Advertisement


David G. Pfister, MD, on Supportive Care in Head and Neck Cancers: Multidisciplinary Management

NCCN 2021 Virtual Annual Conference

Advertisement

David G. Pfister, MD, of Memorial Sloan Kettering Cancer Center, discusses the many considerations when caring for patients with head and neck cancers, such as dental and nutritional issues; side effects from radiation, including necrosis of the bone; oral health; problems with speech; and the concerns of younger patients who may have to cope with the sequelae of treatment such as altered function or disfigurement for years to come.



Related Videos

Prostate Cancer

Sandy Srinivas, MD, on Managing Metastatic Castration-Resistant Prostate Cancer

Sandy Srinivas, MD, of Stanford Cancer Institute, discusses the increasing number of ways to deliver life-prolonging therapy to patients with advanced prostate cancer, including more accurate imaging techniques; PET tracers to help better detect, diagnose, and treat disease; PARP inhibitors for BRCA and other mutations; and new sequencing of drugs.

Skin Cancer

April K. Salama, MD, on Managing Melanoma Brain Metastases

April K. Salama, MD, of Duke Cancer Institute, discusses the shift in recent years, as more effective therapies have become available, toward integrating systemic upfront treatment of patients with brain metastases from cutaneous melanoma; pivotal studies that have provided key data; and the need for a multidisciplinary approach incorporating medical, surgical, and radiation oncology.

Kidney Cancer

Eric Jonasch, MD, on Hereditary Renal Cell Carcinoma: Screening, Diagnosis, and Management

Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the several hereditary renal cell cancer syndromes, the importance of surveillance for both renal and nonrenal manifestations, and the treatment options available.

Issues in Oncology

Shivan J. Mehta, MD, MBA, on Preventing and Controlling HPV-Associated Cancers

Shivan J. Mehta, MD, MBA, of Abramson Cancer Center at the University of Pennsylvania, discusses how insights from behavioral economics could be harnessed to improve HPV vaccination rates, thus lowering the rate of cervical, genital, and head/neck cancers, all of which are linked to HPV.

Bladder Cancer
Immunotherapy

Arlene O. Siefker-Radtke, MD, on Urothelial Bladder Cancer: New Settings for Immune Checkpoint Inhibitors

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses the changing therapeutic landscape in which atezolizumab, avelumab, and pembrolizumab have either been approved or are under review for treating urothelial bladder cancer in the metastatic, superficial, and adjuvant settings.

Advertisement

Advertisement




Advertisement